Commentary|Videos|April 30, 2025
The Evolution of ctDNA Assays in CRC
Author(s)Scott Kopetz, MD, PhD, FACP, Mark A. Lewis, MD
Fact checked by: Chris Ryan
Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved MRD detection in CRC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
3
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5